Tesamorelin for Liver Health
Research, mechanism, dosing, and effectiveness of Tesamorelin for liver health.
Quick Answer
Tesamorelin reduces liver fat in NASH patients.
Evidence Level
FDA Approved
Typical Dose
2 mg daily
Results Timeline
Liver fat reduction over 3-6 months
FDA Status
FDA Approved
How Tesamorelin Works for Liver Health
Visceral fat reduction includes hepatic fat.
About Liver Health
Support for liver function and hepatoprotection.
Research Evidence
FDA approved based on trials showing 15-20% reduction in visceral adipose tissue over 26 weeks. March 2025: FDA approved new F8 formulation (Egrifta WR) with weekly reconstitution, reducing patient burden. CROI 2025 data highlighted limitations of BMI for cardiovascular risk assessment in HIV patients.
Dosing for Liver Health
Recommended Dose
2 mg daily
Frequency
Once daily
Administration
Subcutaneous injection
Duration
Indefinite for approved indication
Note: FDA-approved dose is 2 mg (original) or 1.28 mg (F8/Egrifta WR formulation). Inject subcutaneously in abdomen. F8 requires weekly reconstitution vs daily.
What to Expect
Initial adjustment period. Some users may notice subtle changes.
Early benefits often become noticeable. Continue consistent use.
Most users report meaningful improvements by this point.
Full effects typically realized. Reassess and adjust as needed.
Possible Side Effects
Not everyone experiences these. Individual responses vary.
- •Injection site reactions (common)
- •Joint pain
- •Peripheral edema
- •Pain in extremities
- •Muscle pain
- •Increased diabetes risk
Frequently Asked Questions
Does Tesamorelin help with liver health?
Tesamorelin reduces liver fat in NASH patients.
How does Tesamorelin work for liver health?
Visceral fat reduction includes hepatic fat....
What dose of Tesamorelin should I use for liver health?
2 mg daily
How long until I see results?
Liver fat reduction over 3-6 months
Other Peptides for Liver Health
These peptides are also researched for liver health.
Ipamorelin
Clinical TrialsA selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin. Considered one of the safest GHRPs.
MK-677
Clinical TrialsAn orally active growth hormone secretagogue that mimics ghrelin. Although technically not a peptide, it is frequently discussed alongside GH peptides due to similar effects.
CJC-1295 (No DAC)
Clinical TrialsA synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates GH release from the pituitary. Often combined with a GHRP like Ipamorelin for synergistic effects.
GHRP-6
Clinical TrialsOne of the first synthetic GH secretagogues developed. Strongly stimulates GH release and significantly increases appetite through ghrelin receptor activation.